SANTA MONICA, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13 from 3:00 to 3:25 pm ET. Dr. Roger Crystal, Chief Executive Officer, and Kevin Pollack, Chief Financial Officer, will be delivering an overview of the company and updating investors on the pipeline of products that it is developing for substance use, addictive and eating disorders. Also in attendance will be Arvind Agrawal, Executive Vice President, Medical Affairs, and Dr. Mark Ellison, Executive Vice President Development, Manufacturing and Quality.
In addition to the presentation, management will be meeting with members of the investment community during one-on-one sessions at the conference. Qualified members of the investment community interested in meeting with management are encouraged to do so by contacting their Rodman Conference representative or by calling Cheryl Schneider of Dian Griesel International at 212-825-3210.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. Over 45 million people in the U.S. have one of these disorders. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. by the company’s partner, Adapt Pharma Limited. Currently, Opiant is developing opioid antagonists for the treatment of substance use, addictive and eating disorders, with a near term focus on cocaine use disorder and binge eating disorder (BED). For more information please visit: www.opiant.com.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Contact: Corporate Contact: Investor.email@example.com Media Relations and Investor Relations: Cheryl Schneider or Susan Forman Dian Griesel Int’l. (212) 825-3210
Source:Opiant Pharmaceuticals, Inc.